Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00696423
First received: June 5, 2008
Last updated: November 21, 2012
Last verified: November 2012
  Purpose

This protocol posting deals with objectives & outcome measures of the booster phase. The objectives & outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00412854). This Phase IIIB study will compare GSK Biologicals' DTPa/Hib vaccine to separately administered DTPa and Hib vaccines in Chinese children 18 to 24 months of age, in terms of safety and immunogenicity.


Condition Intervention Phase
Haemophilus Influenzae Type b Disease
Diphtheria
Pertussis
Tetanus
Biological: Infanrix™
Biological: Hiberix™
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Immunogenicity and Reactogenicity Study of GlaxoSmithKline Biologicals' Infanrix™/Hib Vaccine Administered as a Booster Dose to 18-24 Months Old Children

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Anti-polyribosyl-ribitol-phosphate (PRP) Antibody Concentrations [ Time Frame: One month after booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in microgram per milliliter (μg/mL).

  • Anti-diphtheria Toxoid Antibody Concentrations [ Time Frame: One month after booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in international Unit per milliliter (IU/mL).

  • Anti-tetanus Toxoid Antibody Concentrations [ Time Frame: One month after booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in IU/mL.

  • Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibody Concentrations [ Time Frame: One month after booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).

  • The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies [ Time Frame: One month after booster vaccination ] [ Designated as safety issue: No ]
    Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.


Secondary Outcome Measures:
  • Anti-PRP Antibody Concentrations [ Time Frame: Before booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in μg/mL.

  • Anti-diphtheria Toxoid Antibody Concentrations [ Time Frame: Before booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in IU/mL.

  • Anti-tetanus Toxoid Antibody Concentrations [ Time Frame: Before booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in IU/mL.

  • Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations [ Time Frame: Before booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in EL.U/mL.

  • The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies [ Time Frame: Before booster vaccination ] [ Designated as safety issue: No ]
    Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.

  • Number of Subjects Reporting Solicited Local and General Symptoms [ Time Frame: During the 4-day follow-up period after booster vaccination ] [ Designated as safety issue: Yes ]
    Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.

  • Number of Subjects Reporting Unsolicited Adverse Events (AE) [ Time Frame: During the 31-day follow-up period after booster vaccination ] [ Designated as safety issue: No ]
    An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

  • Number of Subjects Reporting Serious Adverse Events (SAE) [ Time Frame: During the 31-day follow-up period after booster vaccination ] [ Designated as safety issue: No ]
    An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in isability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.


Enrollment: 467
Study Start Date: June 2008
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Infanrix/Hib Single Injection Group
Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.
Biological: Infanrix™
Intramuscular injection, one dose
Biological: Hiberix™
Intramuscular injection, one dose
Active Comparator: Infanrix + Hiberix Separate Injection Group
Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.
Biological: Infanrix™
Intramuscular injection, one dose
Biological: Hiberix™
Intramuscular injection, one dose

  Eligibility

Ages Eligible for Study:   18 Months to 24 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
  • Subjects should have completed the full three-dose primary vaccination course in study 104567.
  • A male or female child between, and including, 18 and 24 months of age at the time of the booster vaccination.
  • Written informed consent obtained from the parent or guardian of the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding booster vaccination, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.
  • Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period, with the exception of measles or combined measles, mumps and rubella (MMR) vaccination.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Previous booster vaccination against diphtheria, tetanus, pertussis and/or Haemophilus influenzae type b diseases since the end of the primary study.
  • History of diphtheria, tetanus, pertussis and/or Haemophilus influenzae type b diseases.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s).
  • Major congenital defects or serious chronic illness.
  • History of any progressive neurological disorders or seizures.
  • Acute disease and/or fever at time of enrolment.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.
  • Occurrence of any of the following adverse events (AEs) after previous administration of a diphtheria-tetanus-pertussis (DTP) vaccine:

    • Hypersensitivity reaction due to any component of the vaccine.
    • Encephalopathy.
    • Fever ≥ 40.0 °C (axillary temperature) within 48 hours of vaccination.
    • Collapse or shock-like state within 48 hours of vaccination.
    • Persistent, inconsolable crying occurring within 48 hours of vaccination and lasting ≥ 3 hours.
    • Seizures with or without fever occurring within 3 days of vaccination.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00696423

Locations
China, Guangxi
GSK Investigational Site
Liucheng County, Guangxi, China, 545200
China
GSK Investigational Site
Mengshan, China
GSK Investigational Site
Wuzhou, China
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00696423     History of Changes
Other Study ID Numbers: 111535
Study First Received: June 5, 2008
Results First Received: July 17, 2009
Last Updated: November 21, 2012
Health Authority: China: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
Infanrix/Hib
Chinese children

Additional relevant MeSH terms:
Diphtheria
Influenza, Human
Whooping Cough
Tetanus
Corynebacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Bordetella Infections
Gram-Negative Bacterial Infections
Infection
Clostridium Infections

ClinicalTrials.gov processed this record on April 20, 2014